Joenja leniolisib Updated Sep 12
Joenja's commercial ramp is the key story, watch quarterly Joenja revenue growth, EU launch uptake (starting Germany Q3 2026), and the pending sNDA for lower-weight pediatric patients (13kg to <27kg) submitted July 30, 2026. Phase 3 topline data for ages 1-6 (trial NCT05693129, primary completion July 2026) and Phase 2 CVID data (expected Q4 2026) are potential catalysts. The stock's 52-week low of $9.62 vs. analyst mean target of $34.35 suggests deep value if Joenja execution holds, but the company also faces headwinds from RUCONEST decline and recent revenue guidance cuts.
- Joenja is the first and only approved treatment for APDS, an ultra-rare disease with no direct competitors, strong pricing and orphan drug protections
- Revenue growing rapidly: $14.1M (Q1 2026, +34% YoY) and $17.9M (Q2 2026, +40% YoY), with label expansion to children 4-11 and EU/Japan launches adding new patient segments
- Analyst consensus overwhelmingly bullish: 13 of 14 analysts at Buy/Strong Buy, mean price target $34.35 vs. current ~$11.21 (234% implied upside)
- RUCONEST franchise (hereditary angioedema) is Pharming's larger revenue driver but declining 10-15% YoY, dragging total company growth
- Company lowered 2026 revenue guidance by $30M to $375M-$395M in Q2 2026, and operating profit collapsed to $1.3M from $10.8M a year ago
- Institutional holders are trimming: NewEdge Advisors near-exited (-91.3%), OSAIC near-exited (-87.5%), BNP Paribas trimmed (-25%) in Q2 2026